Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia

Journal of Psychiatry and Neuroscience

Volumn 39, Issue 4, 2014, Pages 276-285

  Kim, Helena Kyunghee ^a   Andreazza, Ana Cristina ^a,b   Yeung, Pok Yik ^a   Isaacs Trepanier, Cameron ^b   Trevor Young, L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DOPAMINE; DOPAMINE TRANSPORTER; REACTIVE OXYGEN METABOLITE; TYROSINE 3 MONOOXYGENASE;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; BLEACHING; CLINICAL EVALUATION; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC TRANSMISSION; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HISTOLOGY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIPID PEROXIDATION; MALE; NITRATION; OXIDATION KINETICS; OXIDATIVE STRESS; POST HOC ANALYSIS; PREFRONTAL CORTEX; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; COMPARATIVE STUDY; MAJOR DEPRESSION; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION;

ADULT; AGED; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PREFRONTAL CORTEX; SCHIZOPHRENIA;

EID: 84902009924     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.130155     Document Type: Article

References (61)

1. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA 2005;293:2528-30.
2. Salvadore G, Quiroz JA, Machado-Vieira R, et al. The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry 2010;71:1488-501.
3. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992;59:1609-23.
4. Scola G, Kim HK, Young LT, et al. A fresh look at complex I in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder. Biol Psychiatry. 2012. doi: S0006-3223(12)00583-5 [pii] 10.1016/j.biopsych.2012.06.028.
5. Andreazza AC, Shao L, Wang JF, et al. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010;67:360-8.
6. Andreazza AC, Kauer-Sant'anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008; 111:135-44.
7. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci 2009; 34: 263-71.
8. Gawryluk JW, Wang JF, Andreazza AC, et al. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011;14:123-30.
9. Kulak A, Steullet P, Cabungcal JH, et al. Redox dysregulation in the pathophysiology of schizophrenia and bipolar disorder: insights from animal models. Antioxid Redox Signal 2013;18:1428-43.
10. Berk M, Dodd S, Kauer-Sant'anna M, et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 2007;(434):41-9.
11. Frey BN, Valvassori SS, Réus GZ, et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 2006;31:326-32.
12. Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011;378:1306-15.
13. Hastings TG, Lewis DA, Zigmond MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A 1996;93:1956-61.
14. Valvassori SS, Rezin GT, Ferreira CL, et al. Effects of mood stabil-izers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J Psychiatr Res 2010;44:903-9.
15. Ciliax BJ, Drash GW, Staley JK, et al. Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 1999;409:38-56.
16. Akil M, Pierri JN, Whitehead RE, et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 1999;156:1580-9.
17. Torrey EF, Webster M, Knable M, et al. The stanley foundation brain collection and neuropathology consortium. Schizophr Res 2000;44:151-5.
18. Mastroberardino PG, Orr AL, Hu X, et al. A FRET-based method to study protein thiol oxidation in histological preparations. Free Radic Biol Med 2008;45:971-81.
19. Waldvogel HJ, Curtis MA, Baer K, et al. Immunohistochemical staining of post-mortem adult human brain sections. Nat Protoc 2006;1:2719-32.
20. Wills J, Jones J, Haggerty T, et al. Elevated tauopathy and alphasynuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010;225:210-8.
21. Miller GW, Staley JK, Heilman CJ, et al. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol 1997;41:530-9.
22. O'Connell LA, Matthews BJ, Ryan MJ, et al. Characterization of the dopamine system in the brain of the túngara frog, Physalaemus pustulosus. Brain Behav Evol 2010;76:211-25.
23. Zhang P, Wang YZ, Kagan E, et al. Peroxynitrite targets the epidermal growth factor receptor, Raf-1, and MEK independently to activate MAPK. J Biol Chem 2000;275:22479-86.
24. Che Y, Wang JF, Shao L, et al. Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. J Psychiatry Neurosci 2010;35:296-302.
25. König P, Krasteva G, Tag C, et al. FRET-CLSM and doublelabeling indirect immunofluorescence to detect close association of proteins in tissue sections. Lab Invest 2006;86:853-64.
26. Keese M, Magdeburg RJ, Herzog T, et al. Imaging epidermal growth factor receptor phosphorylation in human colorectal cancer cells and human tissues. J Biol Chem 2005;280:27826-31.
27. Sharma N, Hewett J, Ozelius LJ, et al. A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence res-onance energy transfer study. Am J Pathol 2001;159:339-44.
28. Hynd MR, Lewohl JM, Scott HL, et al. Biochemical and molecular studies using human autopsy brain tissue. J Neurochem 2003;85:543-62.
29. Selemon LD, Rajkowska G, Goldman-Rakic PS. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J Comp Neurol 1998;392:402-12.
30. Selemon LD, Rajkowska G, Goldman-Rakic PS. Evidence for progression in frontal cortical pathology in late-stage Huntington's disease. J Comp Neurol 2004;468:190-204.
31. Kim HK, Andreazza AC. The relationship between oxidative stress and post-translational modification of the dopamine transporter in bipolar disorder. Expert Rev Neurother 2012;12:849-59.
32. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 2009;35:549-62.
33. Schretlen DJ, Cascella NG, Meyer SM, et al. Neuropsychological functioning in bipolar disorder and schizophrenia. Biol Psychiatry 2007;62:179-86.
34. Potash JB, Bienvenu OJ. Neuropsychiatric disorders: shared genetics of bipolar disorder and schizophrenia. Nat Rev Neurol 2009; 5: 299-300.
35. Maier W, Zobel A, Wagner M. Schizophrenia and bipolar disorder: differences and overlaps. Curr Opin Psychiatry 2006;19:165-70.
36. Ng F, Berk M, Dean O, et al. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsycho pharmacol 2008;11:851-76.
37. Saarelainen T, Hendolin P, Lucas G, et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003;23:349-57.
38. Park SU, Ferrer JV, Javitch JA, et al. Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons. J Neurosci 2002;22:4399-405.
39. Park S, Geddes TJ, Javitch JA, et al. Dopamine prevents nitration of tyrosine hydroxylase by peroxynitrite and nitrogen dioxide: Is nitrotyrosine formation an early step in dopamine neuronal damage? J Biol Chem 2003;278:28736-42.
40. Ara J, Przedborski S, Naini AB, et al. Inactivation of tyrosine hydroxy lase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc Natl Acad Sci U S A 1998;95:7659-63.
41. Blanchard-Fillion B, Souza JM, Friel T, et al. Nitration and inactivation of tyrosine hydroxylase by peroxynitrite. J Biol Chem 2001;276: 46017-23.
42. Daubner SC, Le T, Wang S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 2011;508:1-12.
43. Manji HK, Quiroz JA, Payne JL, et al. The underlying neurobiology of bipolar disorder. World Psychiatry 2003;2:136-46.
44. Almeida JR, Akkal D, Hassel S, et al. Reduced gray matter volume in ventral prefrontal cortex but not amygdala in bipolar disorder: significant effects of gender and trait anxiety. Psychiatry Res 2009; 171:54-68.
45. D'Ardenne K, Eshel N, Luka J, et al. Role of prefrontal cortex and the midbrain dopamine system in working memory updating. Proc Natl Acad Sci U S A 2012;109:19900-9.
46. Glahn DC, Bearden CE, Cakir S, et al. Differential working memory impairment in bipolar disorder and schizophrenia: effects of lifetime history of psychosis. Bipolar Disord 2006;8:117-23.
47. Thompson JM, Gray JM, Hughes JH, et al. Impaired working memory monitoring in euthymic bipolar patients. Bipolar Disord 2007;9:478-89.
48. West MJ. Introduction to stereology. Cold Spring Harb Protoc 2012;2012(8).
49. Winther JR, Thorpe C. Quantification of thiols and disulfides. Biochim Biophys Acta 2013;1840:838-46.
50. Almeida JR, Akkal D, Hassel S, et al. Reduced gray matter volume in ventral prefrontal cortex but not amygdala in bipolar disorder: significant effects of gender and trait anxiety. Psychiatry Res 2009; 171:54-68.
51. Berman KF, Doran AR, Pickar D, et al. Is the mechanism of prefrontal hypofunction in depression the same as in schizophrenia? Regional cerebral blood flow during cognitive activation. Br J Psychiatry 1993;162:183-92.
52. Frey BN, Stanley JA, Nery FG, et al. Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individuals with bipolar disorder: an in vivo 1H MRS study. Bipolar Disord 2007;9(Suppl 1):119-27.
53. López-Larson MP, DelBello MP, Zimmerman ME, et al. Regional prefrontal gray and white matter abnormalities in bipolar disorder. Biol Psychiatry 2002;52:93-100.
54. Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001;49:741-52.
55. Glahn DC, Bearden CE, Cakir S, et al. Differential working memory impairment in bipolar disorder and schizophrenia: effects of lifetime history of psychosis. Bipolar Disord 2006;8:117-23.
56. Thompson JM, Gray JM, Hughes JH, et al. Impaired working memory monitoring in euthymic bipolar patients. Bipolar Disord 2007;9:478-89.
57. Greenacre SA, Ischiropoulos H. Tyrosine nitration: localisation, quantification, consequences for protein function and signal transduction. Free Radic Res 2001;34:541-81.
58. Semendeferi K, Armstrong E, Schleicher A, et al. Prefrontal cortex in humans and apes: a comparative study of area 10. Am J Phys Anthropol 2001;114:224-41.
59. Vawter MP, Tomita H, Meng F, et al. Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. Mol Psychiatry. 2006;11(7):615, 63-79.
60. Chandana R, Mythri RB, Mahadevan A, et al. Biochemical analysis of protein stability in human brain collected at different postmortem intervals. Indian J Med Res 2009;129:189-99.
61. Harish G, Venkateshappa C, Mahadevan A, et al. Glutathione metab olism is modulated by postmortem interval, gender difference and agonal state in postmortem human brains. Neurochem Int 2011;59:1029-42.